Method development and validation for simultaneous estimation of telmisartan and hydrochlorothiazide in bulk and pharmaceutical dosage forms by RP-HPLC

Authors

  • Ayesha Begum K Shadan Women’s College of Pharmacy, Khairatabad, Hyderabad
  • Nabila Quddus Shadan Women’s College of Pharmacy, Khairatabad, Hyderabad
  • Pamu Sandhya Shadan Women’s College of Pharmacy, Khairatabad, Hyderabad
  • D. Ramakrishna Shadan Women’s College of Pharmacy, Khairatabad, Hyderabad

Keywords:

Telmisartan, Hydrochlorothiazide, Precision, Accuracy, Linearity, HPLC

Abstract

An economic, uncomplicated, selective, detailed, and accurate RP-HPLC procedure for simultaneous quantitative determination of telmisartan and hydrochlorothiazide in combined dosage forms was formulated and validated according to ICH guidelines. The method was developed using Agilent 1200 series HPLC and INERTSIL column C18(150x4.6 ID) 5mm in isocratic mode, with mobile phase comprising of sodium dihydrogen phosphate buffer: acetonitrile (30:70) the flow rate was 1.0 ml/min and the detection was carried at a wavelength of 293nm. The retention time and percentage assay of purity for telmisartan and hydrochlorothiazide was found to be 2.853 min and

4.090 min, 100.43% and 99.40% respectively. The method was successfully validated for accuracy, precision, ruggedness, linearity and range, specificity and robustness in accordance with ICH guidelines. The proposed method was found to be within the acceptance limits indicating that the method is accurate, specific and economical.

Downloads

Published

2021-11-12

Issue

Vol. 5 No. 1 (2019): Vol 5, No. 1 (2019) 2019 Volume - 5 Issue-1

Section

Articles

License

Rights and reuse terms depend on the individual article record. Articles accepted on or after 8 September 2026 are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), provided appropriate credit is given, a link to the licence is supplied and changes are indicated. Earlier content remains governed by the rights and licence notice applicable to that article and is not retrospectively relicensed by this policy. Third-party material identified under a different notice is excluded from the journal licence.